Pfizer Gets Final EU Approval For Biosimilar Bevacizumab

 
• By Dave Wallace

Pfizer has received a pan-European marketing authorization for its Zirabev biosimilar bevacizumab, a rival to Genentech’s Avastin. The nod marks Pfizer’s second European approval for an oncology biosimilar.

EuropeSpace
Pfizer Has Received A Pan-European Authorization For Its Avastin Rival • Source: Shutterstock

More from Biosimilars

More from Products